202 related articles for article (PubMed ID: 29137654)
1. Conventional fractionation should not be the standard of care for T2 glottic cancer.
Dixon LM; Douglas CM; Shaukat SI; Garcez K; Lee LW; Sykes AJ; Thomson D; Slevin NJ
Radiat Oncol; 2017 Nov; 12(1):178. PubMed ID: 29137654
[TBL] [Abstract][Full Text] [Related]
2. Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions.
Ermiş E; Teo M; Dyker KE; Fosker C; Sen M; Prestwich RJ
Radiat Oncol; 2015 Sep; 10():203. PubMed ID: 26395876
[TBL] [Abstract][Full Text] [Related]
3. Advantage of accelerated fractionation regimens in definitive radiotherapy for stage II glottic carcinoma.
Nomiya T; Nemoto K; Wada H; Takai Y; Yamada S
Ann Otol Rhinol Laryngol; 2006 Oct; 115(10):727-32. PubMed ID: 17076093
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated radiotherapy for T1N0M0 glottic cancer: retrospective analysis of two different cohorts of dose-fractionation schedules from a single institution.
Laskar SG; Baijal G; Murthy V; Chilukuri S; Budrukkar A; Gupta T; Agarwal JP
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e180-6. PubMed ID: 22862908
[TBL] [Abstract][Full Text] [Related]
5. Accelerated radiotherapy for T1 to T2 glottic cancer.
Motegi A; Kawashima M; Arahira S; Zenda S; Toshima M; Onozawa M; Hayashi R; Akimoto T
Head Neck; 2015 Apr; 37(4):579-84. PubMed ID: 24677592
[TBL] [Abstract][Full Text] [Related]
6. Hyperfractionated accelerated radiotherapy for T1,2 glottic carcinoma. Consideration of time-dose factors.
Sakata K; Someya M; Hori M; Nakata K; Takagi M; Hareyama M
Strahlenther Onkol; 2008 Jul; 184(7):364-9. PubMed ID: 19016035
[TBL] [Abstract][Full Text] [Related]
7. Radiation therapy for T1,2 glottic carcinoma: impact of overall treatment time on local control.
Nishimura Y; Nagata Y; Okajima K; Mitsumori M; Hiraoka M; Masunaga S; Ono K; Shoji K; Kojima H
Radiother Oncol; 1996 Sep; 40(3):225-32. PubMed ID: 8940749
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionation vs. conventional radiotherapy fractionation in the conservative treatment of T1 glottic cancer: a prospective cohort study.
Salas-Salas BG; Domínguez-Nuez DJ; Cabrera R; Ferrera-Alayón L; Lloret M; Lara PC
Clin Transl Oncol; 2020 Jan; 22(1):151-157. PubMed ID: 31152306
[TBL] [Abstract][Full Text] [Related]
9. TN/TN glottic carcinoma: a comparison of two fractionation schedules.
Short S; Krawitz H; Macann A; West T; Morton RP; McIvor NP; Chaplin J; Simcock P; Gathercole J; Dorman B; Hindley A
Australas Radiol; 2006 Apr; 50(2):152-7. PubMed ID: 16635034
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionation reduces the therapeutic ratio in early glottic carcinoma.
Harrison D; Crennan E; Cruickshank D; Hughes P; Ball D
Int J Radiat Oncol Biol Phys; 1988 Aug; 15(2):365-72. PubMed ID: 3403317
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study.
Moon SH; Cho KH; Chung EJ; Lee CG; Lee KC; Chai GY; Kang KM; Lee JY; Chung WK; Park WY; Kim JH
Radiother Oncol; 2014 Jan; 110(1):98-103. PubMed ID: 24161568
[TBL] [Abstract][Full Text] [Related]
12. The impact of conventional or hypofractionated radiotherapy on voice quality and oncological outcome in patients with early glottic cancer.
Di Nicola L; Gravina GL; Marampon F; Bonfili P; Buonopane S; Di Staso M; Festuccia C; Franzese P; Tombolini M; Tombolini V
Oncol Rep; 2010 Nov; 24(5):1383-8. PubMed ID: 20878134
[TBL] [Abstract][Full Text] [Related]
13. Accelerated radiotherapy for T1, 2 glottic carcinoma: analysis of results with KI-67 index.
Sakata K; Oouchi A; Nagakura H; Akiba H; Tamakawa M; Koito K; Hareyama M; Asakura K; Satoh M; Ohtani S
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):81-8. PubMed ID: 10758308
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy for patients with early-stage glottic carcinoma: univariate and multivariate analyses in a group of consecutive, unselected patients.
Franchin G; Minatel E; Gobitti C; Talamini R; Vaccher E; Sartor G; Politi D; Trovò MG; Barzan L
Cancer; 2003 Aug; 98(4):765-72. PubMed ID: 12910521
[TBL] [Abstract][Full Text] [Related]
15. Results of radiotherapy for T2N0 glottic carcinoma: does the "2" stand for twice-daily treatment?
Garden AS; Forster K; Wong PF; Morrison WH; Schechter NR; Ang KK
Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):322-8. PubMed ID: 12527044
[TBL] [Abstract][Full Text] [Related]
16. The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma.
Lyhne NM; Primdahl H; Kristensen CA; Andersen E; Johansen J; Andersen LJ; Evensen J; Mortensen HR; Overgaard J
Radiother Oncol; 2015 Oct; 117(1):91-8. PubMed ID: 26255764
[TBL] [Abstract][Full Text] [Related]
17. Study Protocol: Prospective Study of Concurrent Chemoradiotherapy with S-1 and Hypofractionated Radiotherapy for Outpatients with Early Glottic Squamous Cell Carcinomas.
Kimura K; Itoh Y; Okada T; Kubota S; Kawamura M; Nakahara R; Oie Y; Kozai Y; Takase Y; Tsuzuki H; Nishio N; Hiramatsu M; Fujimoto Y; Mizutani T; Hirakawa A; Naganawa S
Asian Pac J Cancer Prev; 2018 May; 19(5):1195-1199. PubMed ID: 29801401
[TBL] [Abstract][Full Text] [Related]
18. Patterns of Care for Patients With Early-Stage Glottic Cancer Undergoing Definitive Radiation Therapy: A National Cancer Database Analysis.
Stokes WA; Abbott D; Phan A; Raben D; Lanning RM; Karam SD
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1014-1021. PubMed ID: 28721883
[TBL] [Abstract][Full Text] [Related]
19. T1-T2 squamous cell carcinoma of the glottic larynx treated with radiation therapy: relationship of dose-fractionation factors to local control and complications.
Mendenhall WM; Parsons JT; Million RR; Fletcher GH
Int J Radiat Oncol Biol Phys; 1988 Dec; 15(6):1267-73. PubMed ID: 3143690
[TBL] [Abstract][Full Text] [Related]
20. Patterns of fractionation for patients with T2N0M0 glottic larynx cancer undergoing definitive radiotherapy in the United States.
Stokes WA; Stumpf PK; Jones BL; Blatchford PJ; Karam SD; Lanning RM; Raben D
Oral Oncol; 2017 Sep; 72():110-116. PubMed ID: 28797446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
